Clinical trial
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With…
NCT00070265 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00070265 |
|---|---|
| Title | Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer |
| Official title | A Multi-Institutional Phase II Trial Of Neoadjuvant Capecitabine (XELODA) And Oxaliplatin (ELOXATIN) For Resectable Colorectal Metastases In The Liver |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer |
| Intervention type | Drug, Other, Procedure |
| Interventions | oxaliplatin, capecitabine, therapeutic conventional surgery, laboratory biomarker analysis |
| Enrollment | 80 |
| Start date | Aug 1, 2003 |
| Primary completion | Sep 1, 2004 |
| First posted | Oct 7, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: